Levamlodipine benzenesulfonate is the ingredient of Schwerta and Metoprolol is the ingredient of Betalucil, which are used in combination for the treatment of hypertension. Levamlodipine besylate is a calcium antagonist, which can lower blood pressure by dilating peripheral blood vessels. Metoprolol can lower blood pressure by inhibiting beta receptors, and can slow down the heart rate and reduce myocardial oxygen consumption, the two together can play a synergistic role in lowering blood pressure. Adverse effects of levamlodipine besylate include dizziness, headache, edema, fatigue, flushing, palpitations (rapid heartbeat, often accompanied by panic), etc. It is contraindicated in patients who are allergic to the components of the drug. Adverse reactions to metoprolol include headache, dizziness, stomach pain, constipation, bradycardia, decreased blood pressure, conduction tissue. It is contraindicated in patients with hypersensitivity to the components of the drug, non-compensated heart failure, cardiovascular shock, significant bradycardia, hypotension, severe heart failure, bronchial asthma. When taking levamlodipine benzenesulfonate and metoprolol orally to control blood pressure in patients with hypertension, it is necessary to use the drug under the supervision of a physician and choose the appropriate dose.